President Trump’s recent appointment of Kyle Diamantas as acting FDA commissioner following Marty Makary’s May 12 resignation has elevated Diamantas to the leading position in trader assessments for a permanent announcement. As the agency’s former deputy commissioner for food policy, Diamantas now oversees daily operations and aligns with administration priorities on food safety and regulatory reform, giving him an insider advantage during the ongoing White House search. Other names such as Stephen Hahn, Sara Brenner, Brett Giroir, and Grace Graham remain in consideration but trail due to less direct involvement in the current transition. The 21 percent probability assigned to no announcement by year-end reflects the typical timeline for Senate confirmation of a new commissioner, with traders weighing procedural delays against the administration’s stated intent to move quickly.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-updateKyle Diamantas 53%
No announcement by December 31 15.9%
Stephen Hahn 4%
Brett Giroir 3.3%
BAGO
BAGO
Dec 31, 2026
Kyle Diamantas
53%
Stephen Hahn
4%
Brett Giroir
3%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
16%
Kyle Diamantas 53%
No announcement by December 31 15.9%
Stephen Hahn 4%
Brett Giroir 3.3%
BAGO
BAGO
Dec 31, 2026
Kyle Diamantas
$1,525 Vol.
53%
Stephen Hahn
$976 Vol.
4%
Brett Giroir
$1,510 Vol.
3%
Grace Graham
$1,893 Vol.
3%
Sara Brenner
$849 Vol.
3%
No announcement by December 31
$533 Vol.
16%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump’s recent appointment of Kyle Diamantas as acting FDA commissioner following Marty Makary’s May 12 resignation has elevated Diamantas to the leading position in trader assessments for a permanent announcement. As the agency’s former deputy commissioner for food policy, Diamantas now oversees daily operations and aligns with administration priorities on food safety and regulatory reform, giving him an insider advantage during the ongoing White House search. Other names such as Stephen Hahn, Sara Brenner, Brett Giroir, and Grace Graham remain in consideration but trail due to less direct involvement in the current transition. The 21 percent probability assigned to no announcement by year-end reflects the typical timeline for Senate confirmation of a new commissioner, with traders weighing procedural delays against the administration’s stated intent to move quickly.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Binuksan ang Market: May 12, 2026, 7:59 PM ET
Volume
$7,286Petsa ng Pagtatapos
Dec 31, 2026Binuksan ang Market
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump’s recent appointment of Kyle Diamantas as acting FDA commissioner following Marty Makary’s May 12 resignation has elevated Diamantas to the leading position in trader assessments for a permanent announcement. As the agency’s former deputy commissioner for food policy, Diamantas now oversees daily operations and aligns with administration priorities on food safety and regulatory reform, giving him an insider advantage during the ongoing White House search. Other names such as Stephen Hahn, Sara Brenner, Brett Giroir, and Grace Graham remain in consideration but trail due to less direct involvement in the current transition. The 21 percent probability assigned to no announcement by year-end reflects the typical timeline for Senate confirmation of a new commissioner, with traders weighing procedural delays against the administration’s stated intent to move quickly.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volume
$7,286Petsa ng Pagtatapos
Dec 31, 2026Binuksan ang Market
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...President Trump’s recent appointment of Kyle Diamantas as acting FDA commissioner following Marty Makary’s May 12 resignation has elevated Diamantas to the leading position in trader assessments for a permanent announcement. As the agency’s former deputy commissioner for food policy, Diamantas now oversees daily operations and aligns with administration priorities on food safety and regulatory reform, giving him an insider advantage during the ongoing White House search. Other names such as Stephen Hahn, Sara Brenner, Brett Giroir, and Grace Graham remain in consideration but trail due to less direct involvement in the current transition. The 21 percent probability assigned to no announcement by year-end reflects the typical timeline for Senate confirmation of a new commissioner, with traders weighing procedural delays against the administration’s stated intent to move quickly.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update
Mag-ingat sa mga external link.
Mag-ingat sa mga external link.
Mga Madalas na Tanong